Tumor Necrosis Factor Alpha News and Research

RSS

Drug infliximab may help ease ulcerative colitis

In good news for patients with stubborn cases of ulcerative colitis, a serious intestinal disorder, a new research review suggests that the drug infliximab can be a useful alternative if other treatments don't work.

12 Sep 2006

Tumor necrosis factor A antagonist use and cancer in patients with rheumatoid arthritis

Patients with rheumatoid arthritis (RA), an autoimmune, inflammatory disease marked by progressive joint and organ damage, face a high risk of developing cancer.

31 Aug 2006

Arthritis drug wins approval for use in children with Crohn's disease

The Food and Drug Administration in the U.S. has given approval for the drug Remicade for use in children with active Crohn's disease(CD), a chronic and debilitating condition.

21 May 2006

Thalidomide, Lenalidomide show promise against Lou Gehrig's disease

New animal research suggests that two well-studied drugs, thalidomide and its derivative, lenalidomide, might extend the survival of patients with the neurological disorder amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

9 Mar 2006

Lab-made version of a human protein opens a new research avenue to better understand rheumatoid arthritis

A lab-made version of a human protein alleviates symptoms of both acute and chronic arthritis in mice and could be the basis for a new arthritis drug for people, report scientists from the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH).

3 Oct 2005

Depression may hasten the progression of heart disease

In a study of 32 people with heart failure, the 14 patients who felt the most depressed had nearly twice the levels of this protein in their blood.

7 Sep 2005

Discovery of gene STAT6(B) may lead to new treatments for inflammatory diseases

In a paper featured in Proceedings of the National Academy of Science (PNAS), researchers from Boston University School of Dental Medicine report the discovery of a new gene, STAT6(B), that helps regulate production of the potentially deadly tumor necrosis factor alpha (TNF-alpha) cytokine.

28 Mar 2005

Body fat may promote inflammation

Why does extra fat around the waist increase the risk of heart disease? A new study by Wake Forest University Baptist Medical Center researchers and colleagues suggests that inflammation may be the key.

28 Mar 2005

Biologic therapies are changing the way dermatologists treat psoriasis

Recently approved and investigational biologic therapies are changing the way dermatologists treat psoriasis, a chronic disease that physically and emotionally challenges 4.5 million Americans. As more research is conducted into the effectiveness of these biologics, they are showing great promise for improving the health and well-being of patients with psoriasis.

20 Feb 2005

African Americans more likely to carry genetic variants known to stimulate inflammatory response

Specific variants in genes that encode proteins regulating inflammation may hold a key to explaining a host of disease processes known to cause increased risk of illness and death among African Americans, according to a study from the University of Pittsburgh's Graduate School of Public Health (GSPH).

1 Dec 2004

Analysis shows Remicade reduces pain associated with Crohn's disease

According to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen) trial patients who received a three-dose induction regimen of Remicade experienced a significantly greater reduction in pain as assessed by four different pain questions after ten weeks, compared with patients who received a single dose of Remicade.

2 Nov 2004

New anti-inflammatory strategy for cancer therapy

A new strategy for cancer therapy, which converts the tumor-promoting effect of the immune system’s inflammatory response into a cancer-killing outcome, is suggested in research findings by investigators at the University of California, San Diego (UCSD) School of Medicine.

20 Sep 2004

Remicade shows improvement in both the arthritis and psoriasis associated with psoriatic arthritis

In this trial, REMICADE provided a 70 percent improvement (as measured by ACR 70) in symptoms of arthritis in nearly one-third of patients, compared with only 2 percent of patients on placebo at 24 weeks.

10 Jun 2004

3 or 4 glasses of wine a week can kill cancer cells

It’s well known that drinking red wine in moderation can have some health benefits, mainly attributed to a compound called resveratrol. Now, scientists at the University of Virginia Health System have discovered how.

25 May 2004

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Centocor, Inc., and Schering-Plough Corporation announced today the initiation of the SONIC (Study of Immunomodulator Naive patients in Crohn's Disease) trial that will evaluate the efficacy of REMICADE® (infliximab) versus azathioprine, a conventional immunosuppressive agent, alone and versus the combination of both drugs for the treatment of patients with Crohn's disease.

18 May 2004

500,000 patients have now been treated with REMICADE® worldwide

Centocor, Inc., announced today that more than a half million patients worldwide have now been treated with the anti-TNF agent REMICADE® (infliximab) since it was introduced in the United States five years ago.

21 Apr 2004

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.

6 Apr 2004